Skip to main content
NORTHEAST PHARMACEUTICAL GROUP CO.,LTD logo

NORTHEAST PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 000597 ISIN · CNE0000009G0 LEI · 300300HX6JTMOEENF158 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,606 across all filing types
Latest filing 2024-03-29 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000597

About NORTHEAST PHARMACEUTICAL GROUP CO.,LTD

https://www.nepharm.com.cn

Northeast Pharmaceutical Group Co., Ltd. (NEPG) specializes in the research, development, manufacture, and distribution of active pharmaceutical ingredients (APIs) and finished dosage forms. The company operates as a large-scale integrated pharmaceutical enterprise with a diverse product portfolio encompassing vitamins, antibiotics, cardiovascular agents, and digestive system medications. NEPG is recognized as a global leader in the production of Vitamin C and Vitamin B1, alongside significant output in caffeine and fosfomycin. Its manufacturing facilities adhere to international quality standards, including Good Manufacturing Practice (GMP) certifications. The company serves a broad international market, exporting products to numerous countries while maintaining a strong domestic presence. NEPG focuses on technological innovation and industrial scaling to provide high-quality chemical raw materials and pharmaceutical preparations for global healthcare needs.

Recent filings

Filing Released Lang Actions
关于公司及子公司2024年度金融机构授信总额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the total credit limit for financing from financial institutions for the year 2024 for the company and its subsidiaries. It includes details about the credit amounts, types of financing, and guarantees, as well as references to board and supervisory committee meeting resolutions. The document is relatively short (1477 characters) and does not contain actual financial statements or detailed financial performance data. It is an update on financing activities and credit limits, which fits the category of Capital/Financing Update (CAP).
2024-03-29 Chinese
关于公司为全资子公司提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 东北制药集团股份有限公司 regarding the provision of guarantees for its wholly-owned subsidiaries. It includes detailed information about the guarantee amounts, the subsidiaries involved, their financial data, and the board's opinions on the guarantees. The document is a formal disclosure about financing-related activities, specifically guarantees provided to subsidiaries to support their credit lines. It does not contain a full financial report, audit report, or earnings release. It is not a report publication announcement since it contains substantive details rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company to its subsidiaries.
2024-03-29 Chinese
关于公司2023年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Dongbei Pharmaceutical Group Co., Ltd. regarding the company's 2023 annual asset impairment provision. It details the amounts of impairment provisions made and reversed, the accounting policies and methods used for impairment testing, and the impact on the company's 2023 profit. It also includes opinions from the supervisory board and audit committee, and mentions that the impairment provision was audited with an unqualified opinion. The document is relatively short (3314 characters) and focuses on a specific accounting adjustment rather than presenting a full annual report or comprehensive financial statements. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a certification or regulatory filing. It is a specific announcement about asset impairment provisions, which is typically classified under Regulatory Filings (RNS) as it does not fit the other more specific categories and is an announcement of accounting adjustments rather than a full report or presentation.
2024-03-29 Chinese
监事会关于公司内部控制自我评价报告的意见
Audit Report / Information Classification · 95% confidence The document is a supervisory board opinion on the company's internal control self-evaluation report for the year 2023. It references regulatory guidelines related to internal control and compliance with securities laws and stock exchange regulations. The content focuses on internal control evaluation and supervisory board's opinion rather than presenting full financial statements or audit results. The document length is short (610 characters), and it does not contain detailed financial data or audit findings. It is not an annual report, audit report, or interim report. It is also not an announcement of voting results, management changes, or capital updates. The document fits best under Audit Report / Information (AR) as it relates to internal control evaluation and supervisory opinion on internal controls, which is a type of audit-related information. FY 2023
2024-03-29 Chinese
2023年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2023年度监事会工作报告" (2023 Supervisory Board Work Report) of Northeast Pharmaceutical Group Co., Ltd. It details the supervisory board's activities, meetings, oversight of financial reports, internal controls, compliance with laws and regulations, and plans for 2024. The content focuses on the supervisory board's review and oversight functions rather than presenting full financial statements or detailed financial performance data. The document length is 3737 characters, which is relatively short and consistent with a report or summary rather than a full annual report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not an announcement or certification but a substantive report on supervisory activities. Given the nature of the content, this document best fits the category of a Management Report (MDA), which includes management's detailed explanation of business trends, oversight, and outlook, especially from the supervisory board perspective.
2024-03-29 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 25th meeting of the 9th Board of Directors of Dongbei Pharmaceutical Group Co., Ltd. It includes voting results on various proposals related to the company's 2023 annual report, financial statements, remuneration, audit appointments, profit distribution, internal control reports, accounting policy changes, and other governance matters. The document references multiple related reports and announcements published on the same day but does not contain the full annual report or financial statements itself. It is a formal board meeting resolution announcement that will be submitted to the 2023 annual general meeting for approval. Given the content and nature, this fits best under Board/Management Information (MANG) as it concerns board meeting decisions and management reports rather than the full annual report or other filings.
2024-03-29 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.